Digital Thermal Monitoring for Endothelial Dysfunction

KM
DR
Overseen ByDristhi Ragoonanan
Age: < 65
Sex: Any
Trial Phase: Academic
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a device called Vendys II to assess blood vessel health in children and young adults undergoing hematopoietic cell transplantation (HCT). The device uses digital thermal monitoring to measure blood vessel response after temporarily restricting blood flow. The trial aims to determine if this method is feasible for children and young adults who are HCT candidates. Suitable participants are those aged 6-26 who are about to undergo or have recently undergone HCT. As an unphased trial, this study allows participants to contribute to innovative research that could enhance future HCT outcomes.

Do I have to stop taking my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications.

What prior data suggests that the Vendys II device is safe for measuring vascular health?

Research has shown that the Vendys II device, used for checking blood flow, is safe. Studies with similar devices have reported no problems, indicating that people generally tolerate it well.

The FDA has approved the Vendys II, confirming it has passed safety tests for specific uses. As a noninvasive tool, it does not involve surgery or entering the body, making it safer than more invasive treatments.

Overall, evidence suggests that the Vendys II device is safe for measuring blood vessel health.12345

Why are researchers excited about this trial?

Researchers are excited about the Vendys II Device because it offers a new, non-invasive way to assess blood vessel health by measuring temperature changes in the fingertips. Unlike traditional methods for evaluating endothelial dysfunction, which might require more invasive procedures or complex imaging, this device provides quick and easy monitoring. This approach helps in early identification of potential cardiovascular issues, potentially leading to better prevention strategies and personalized treatment plans.

What evidence suggests that the Vendys II device is effective for evaluating vascular health in children and adolescents undergoing HCT?

Studies have shown that the Vendys II device, used by participants in this trial, effectively measures blood vessel function, crucial for heart and blood health. This device assesses how blood vessels respond to changes in blood flow. It is fully automated and non-invasive, requiring no surgery or needles. Research indicates that it accurately measures changes in blood flow and vessel health. These findings suggest it could benefit patients undergoing treatments like hematopoietic cell transplantation, where monitoring blood vessel health is important.13467

Who Is on the Research Team?

KS

Keri Schadler

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

This trial is for children and young adults aged 6-26 who are about to undergo or have recently had a hematopoietic cell transplant (HCT). It includes both recipients within a month before/after HCT and healthy donors. Participants must fit the device on their index finger without pain or difficulty, consent to join, and not have skin toxicity or neuropathy affecting device use.

Inclusion Criteria

I am a healthy donor aged 6-26 for hematopoietic cell transplantation.
I have had a stem cell transplant within the last month or plan to have one in the next two weeks.
Willing and eligible to enroll on PA19-0756
See 2 more

Exclusion Criteria

Any subject who does not consent/assent to participation.
You have an injury or deformity on your index finger that would make it impossible to wear the device comfortably.
I cannot use the device comfortably due to skin issues or nerve pain.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Assessment

Participants undergo a single measurement of vascular health using the Vendys II device

1 day
1 visit (in-person)

Follow-up

Participants are monitored for any adverse events following the assessment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Vendys II Device
Trial Overview The study is testing the Vendys II device's ability to measure vascular health in patients undergoing HCT. The FDA-approved tool assesses how well blood vessels can dilate by monitoring temperature changes in the finger after temporarily stopping blood flow.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Vendys II DeviceExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

Published Research Related to This Trial

A study involving 56 patients with Continuous Flow-Left Ventricular Assist Devices (CF-LVADs) found that poor endothelial function, measured by the VENDYS® device, is linked to a significantly higher risk of future bleeding events, particularly neurologic bleeds.
The vascular reactivity index (VRI) from the VENDYS® test can effectively predict adverse outcomes, with a VRI less than 1 indicating a 5.56 times greater hazard for bleeding events, suggesting that monitoring endothelial function could be crucial for patient management.
Endothelial Dysfunction-related Neurological Bleeds with Continuous Flow-Left Ventricular Assist Devices Measured by Digital Thermal Monitor.Ali, A., Uribe, C., Araujo-Gutierrez, R., et al.[2021]
A new microfluidic device allows for real-time monitoring of endothelial permeability and adhesion protein expression, which are crucial for understanding cardiovascular disease progression.
The study found that changes in endothelial response occur at specific oscillatory shear stress frequencies, indicating that there is a threshold frequency that triggers significant changes in endothelial function.
Detection of frequency-dependent endothelial response to oscillatory shear stress using a microfluidic transcellular monitor.Sei, YJ., Ahn, SI., Virtue, T., et al.[2019]
A new method using digital thermal monitoring (DTM) can effectively measure peripheral vascular reactivity, providing a simpler and more cost-effective alternative to traditional Doppler systems.
The study demonstrated that DTM-derived flow signals closely matched those obtained from Doppler sensors, with a reactivity response difference of only +/- 15%, indicating that DTM can reliably assess vascular function in cardiovascular screenings.
Digital thermal monitoring (DTM) of vascular reactivity closely correlates with Doppler flow velocity.McQuilkin, GL., Panthagani, D., Metcalfe, RW., et al.[2021]

Citations

Endothelial Function Test | VENDYS-II is FDA Cleared & ...Improve patient care and bottom line with VENDYS-II. The first fully automated, office-based, noninvasive Endothelial Function testing device.
PatientsEndothelial function is a vital component of vascular function that enables adjustments of blood flow and alterations of vessel tone and diameter, when needed.
A novel operator-independent noninvasive device for ...A novel device that provides an automated measurement of the difference between baseline and post-ischemic, hyperemia-induced, brachial arterial compliance.
Digital Thermal Monitoring for Endothelial DysfunctionTrial Overview The study is testing the Vendys II device's ability to measure vascular health in patients undergoing HCT. The FDA-approved tool assesses how ...
High Frequency of Microvascular Dysfunction in US ...All DTM tests were performed using a VENDYS device (Endothelix, Palo Alto, CA), a nonimaging, simplified system that fully automates the arm- ...
Endothelial Function Test | VENDYS-II is FDA Cleared & ...FDA-Cleared & Fully Automated · The only FDA cleared, fully automated, noninvasive vascular reactivity and endothelial function test in the US. · Reimbursable ...
New Indices of Endothelial Function Measured by Digital ...DTM measures were correlated with age, sex, heart rate, and systolic and diastolic blood pressure in 6084 patients from 18 clinics.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security